anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Initiating Treatment with Codeine Sulfate Tablets:

Initiate treatment with codeine sulfate tablets in a dosing range of 15 to 60 mg every 4 hours as needed for pain, and at the lowest dose necessary to achieve adequate analgesia. Titrate the dose based upon the individual patient’s response to their initial dose of codeine sulfate tablets. Adult doses of codeine sulfate tablets higher than 60 mg provide no further efficacy but are associated with greater adverse reactions. The maximum 24-hour dose is 360 mg.

Conversion from Other Opioids to Codeine Sulfate Tablets:

There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of codeine sulfate tablets. It is safer to underestimate a patient’s 24-hour codeine sulfate tablets dosage than to overestimate the 24-hour codeine sulfate tablets dosage and manage an adverse reaction due to overdose.
After dental extraction, a physiological phenomenon of reabsorption of the dentoalveolar process is triggered, especially if periradicular lesions are present, which can sometimes be associated with oroantral communication in the upper posterior maxilla. To investigate a minimally invasive approach, 19 patients undergoing tooth extraction in the posterosuperior maxilla were recruited. All cases presented an oroantral communication with a diameter of 2-5 mm after tooth extraction and the alveolar process and, in some cases, with a partial defect of 1 or more bony walls. In these cases, a single surgical procedure was used to preserve the alveolar ridge using an open barrier technique with an exposed dense polytetrafluoroethylene membrane. The bottom of the extraction socket was filled with a collagen fleece. The residual bone process was reconstructed using a biomaterial based on carbonate-apatite derived from porcine cancellous bone. After 6 months, all patients were recalled and subjected to radiographic control associated with an implant-prosthetic rehabilitation plan. Data relating to the sinus health status and the average height and thickness of the regenerated bone were collected. Radiographic evaluation verified the integrity of the maxillary sinus floor with new bone formation, detecting a vertical bone dimension between 3.1 mm and 7.4 mm (average 5.13 ± 1.15 mm) and a horizontal thickness between 4.2 mm and 9.6 mm (average 6.86 ± 1.55 mm). The goal of this study was to highlight the advantage of managing an oroantral communication and, simultaneously, obtain the preservation and regeneration of the alveolar bone crest. The open barrier technique appears to be effective for the minimally invasive management of oroantral communication up to 5 mm in diameter in postextraction sites, with a good regeneration of hard and soft tissue.
A pharmaceutical composition for preparing nano/micro bubbles for drug delivery. The present invention provides a pharmaceutical composition for forming a plurality of bubbles for drug delivery. The pharmaceutical composition includes a drug layer comprising an active ingredient, a surfactant, an acidic ingredient, and a foaming agent. The active ingredient comprises a nucleic acid, polypeptide or protein. The foaming agent and the acidic component in the drug layer react to generate carbon dioxide after dissolving in water, thereby forming bubbles. The bubbles surround the carbon dioxide gas core with a surfactant and form a double-layer structure, wherein the double-layer structure has an inner layer and an outer layer, and the active ingredient is embedded in a gap formed between the inner layer and the outer layer of the double-layer structure.
<P>PROBLEM TO BE SOLVED: To obtain a slimming sheet material which is applied to the human skin, cools the skin surface, efficiently promotes blood circulation and burns and decomposes fats.  <P>SOLUTION: This slimming sheet material 1 is constituted of a sheet material 2 and a liniment applied to one side of the sheet material 2. The liniment 3 comprises a refreshing stimulant for providing the skin with a feeling of cold or a refreshing feeling when applied to the skin, a blood circulation promoter for improving blood circulation, a fat decomposition composition for decomposing or burning fats of the human body, a viscosity adjuster and water and/or an alcohol. Camphor is used as the refreshing stimulant. Guinea pepper essence, Citrus unshiu Mercov essence and ginger essence are used as the blood circulation promoter. Caffeine is used as the fat decomposition composition. A release sheet 4 made of polypropylene is bonded to the exposed surface of the liniment 3 of the slimming sheet material 1.  <P>COPYRIGHT: (C)2004,JPO
Sepsis-induced myocardial dysfunction (SIMD), also known as sepsis-induced cardiomyopathy (SICM), is linked to significantly increased mortality. Despite its clinical importance, effective therapies for SIMD remain elusive, largely due to an incomplete understanding of its pathogenesis. Over the past five decades, research involving both animal models and human studies has highlighted several pathogenic mechanisms of SICM, yet many aspects remain unexplored. Initially thought to be primarily driven by inflammatory cytokines, current research indicates that these alone are insufficient for the development of cardiac dysfunction. Recent studies have brought attention to additional mechanisms, including excessive nitric oxide production, mitochondrial dysfunction, and disturbances in calcium homeostasis, as contributing factors in SICM. Emerging clinical evidence has highlighted the significant role of myocardial edema in the pathogenesis of SICM, particularly its association with cardiac remodeling in septic shock patients. This review synthesizes our current understanding of SIMD/SICM, focusing on myocardial edema's contribution to cardiac dysfunction and the critical role of the bradykinin receptor B1 (B1R) in altering myocardial microvascular permeability, a potential key player in myocardial edema development during sepsis. Additionally, this review briefly summarizes existing therapeutic strategies and their challenges and explores future research directions. It emphasizes the need for a deeper understanding of SICM to develop more effective treatments.
The invention discloses a data storage method and a system for a detection report; the data storage method comprises the following steps: and S1, establishing a task table to be forwarded and a data storage table of the detection report. And S2, acquiring the tasks to be transferred, and sequentially recording the tasks to be transferred into the task table to be transferred. The task to be relayed comprises basic information of the detected crowd and a detection report of the detected crowd. And S3, adjusting the tasks to be forwarded in the task table to be forwarded according to the preset priority level, and determining the current tasks to be forwarded in the task table to be forwarded. And S4, acquiring the reachable mode in the task table to be reached, and judging whether the reachable mode exists in the current task to be reached. If so, the current task to be transferred is transferred immediately and transferred into the data storage table, otherwise, the current task to be transferred is skipped over and inserted into the task table to be transferred according to a preset insertion method. The method ensures that each task to be transferred can be executed in order according to the priority and the time sequence.
BACKGROUND & AIMS: Previous studies have suggested an increased risk of major adverse liver outcomes (MALO) in relatives of patients with metabolic dysfunction-associated steatotic liver disease (MASLD). However, granular and longitudinal evidence is lacking on the future risk of MALO among family members of individuals with MASLD.
METHODS: We identified 3526 first-degree relatives (FDRs) and 11 079 general population comparators to 1328 patients with MASLD diagnosed between 1974 and 2021, with detailed clinical data, including liver histology in 71% of patients. MALO was defined through diagnostic coding for cirrhosis or its complications. Cox regression models were used to estimate adjusted hazard ratios (aHRs) for MALO among FDRs compared to general population comparators. Cumulative incidence accounting for competing risks was calculated.
RESULTS: During a median follow-up of 13.4 years, there were 65 (2%, 1.12/1000 person-years) and 225 (2%, 1.26/1000 person-years) MALO events in FDRs and general population comparators respectively. After adjusting for demographic factors and comorbidities, FDRs were at no increased risk of MALO (aHR = 0.99, 95% CI: 0.74-1.33). Increased relative rates of MALOs were, however, observed in some subgroups, including parents, although absolute risk estimates were low and comparable to the general population.
CONCLUSIONS: FDRs of patients with MASLD did not have a higher rate of incident MALO than the general population. Since the absolute risk of MALO in relatives of patients with MASLD was low, these results do not support systematic screening of MASLD-related fibrosis in relatives of patients with MASLD.
Patients whose tumor was not fully removed at the time of initial surgery receive WP1066 PO for 6 weeks during routine radiation therapy on study. Patients may then undergo possible surgery or open biopsy if eligible, followed by twelve 28-day cycles of WP1066 PO on study. Patients also undergo MRI and collection of blood samples throughout the trial.
HIV-negative TGW will have HIV testing using the 4th generation immunoassays/nucleic acid testing (NAT) in acute HIV testing algorithm currently used at the Thai Red Cross Anonymous Clinic at week 5, 8, and 15. Creatinine clearance will be performed at week 15.
The invention relates to a medicine preparation technology, and aims to provide a method for preparing a medicine for treating hypertension by using dendrobium officinale and radish seed as main materials. The method comprises the following steps: grinding parched Raphani semen, radix Ophiopogonis and radix Paeoniae alba respectively, mixing, extracting with hot water, and concentrating to obtain water extract concentrate; grinding herba Dendrobii into powder, and adding into the concentrated water extract; adding auxiliary materials and forming. Or grinding the four medicinal materials into powder, and then carrying out alcohol extraction: adding 75% ethanol 5 times of the crude drug, extracting at 60 deg.C for 24 hr for 2 times, and recovering ethanol; after alcohol extraction, the residue is further treated with water extraction, concentrated and the extracted liquid is combined. Adding auxiliary materials and forming. The medicine prepared by the invention is suitable for treating hypertension with yin deficiency or yin deficiency and yang hyperactivity, accompanied by restlessness of heart and insomnia; or the western medicine antihypertensive drug is used together for treatment, so that the dosage of the western medicine antihypertensive drug is reduced. It is also suitable for patients with mild hypertension or normal hypertension.
Participants in this group will receive Sudapyridine (WX-081) combined with background regimen (BR). Treatment starts with a loading dose of Sudapyridine for 2 weeks (450 mg once daily for 7 days, followed by 300 mg once daily for 7 days). This is followed by a maintenance dose of 150 mg once daily from Week 3 to Week 24. During the 24-week treatment period, participants will also receive a placebo for bedaquiline and continue their background regimen (BR). After the 24-week treatment period, participants will enter the background regimen phase and continue BR until Week 72.
Coagulation disorders are on top of the list of extracorporeal-membrane oxygenation (ECMO) complications. They contribute significantly to morbidity and mortality of ECMO patients. This observational study aims to evaluate coagulation profiles of ECMO patients treated on the intensive care units of the Department of Anaesthesiology of LMU Munich. Adult ECMO patients are included in the study after informed consent.

Bleeding and thromboembolic complications as well as treatment details are recorded. Additional coagulation laboratory markers (such as von-Willebrand-factor, ADAMTS13-protease, platelet function tests and thromboelastometric tests) are correlated with clinical signs of bleeding. Regular ultrasound examination of the large vessels are performed to Screen for thrombosis.
To date, pure-tone audiometry remains the gold standard for clinical auditory testing. However, pure-tone audiometry is time-consuming and only provides a discrete estimate of hearing acuity. Here, we aim to address these two main drawbacks by developing a machine learning (ML)-based approach for fully automated bone-conduction (BC) audiometry tests with forehead vibrator placement. Study 1 examines the occlusion effects when the headphones are positioned on both ears during BC forehead testing. Study 2 describes the ML-based approach for BC audiometry, with automated contralateral masking rules, compensation for occlusion effects and forehead-mastoid corrections. Next, the performance of ML-audiometry is examined in comparison to manual and conventional BC audiometry with mastoid placement. Finally, Study 3 examines the test-retest reliability of ML-audiometry. Our results show no significant performance difference between automated ML-audiometry and manual conventional audiometry. High test-retest reliability is achieved with the automated ML-audiometry. Together, our findings demonstrate the performance and reliability of the automated ML-based BC audiometry for both normal-hearing and hearing-impaired adult listeners with mild to severe hearing losses.
A total of 40 participants were evenly split, with 20 in each of the two dosage groups, to receive the investigational cAd3-Marburg vaccine at a dose of either 1x10\^10 particle units (PU) (Group 1) or 1x10\^11 PU (Group 2). The dose escalation plan included daily review of any new safety data by a study clinician, regular review of safety data by the protocol team and a staged enrollment plan with required interim safety reviews. The study began with enrollment of 3 participants into Group 1 (1x10\^10 PU) at a rate of 1 participant per day. After at least 7 days of follow-up for the first 3 vaccinated participants, an interim safety review occurred before enrollment of additional participants into the group. No safety issues were identified; therefore, an additional 17 participants were enrolled to complete Group 1. When there was a minimum of seven days of follow-up safety data from the last enrolled participant in Group 1, an interim safety review occurred. Once no safety issues were identified, enrollment of participants into the next dose level began with the enrollment of 3 participants at a rate of 1 participant per day. After at least 7 days of follow-up for the first 3 vaccinated participants in Group 2 (1x10\^11 PU), an interim safety review occurred before the enrollment of additional participants into Group 2. No safety issues were identified and an additional 17 participants were enrolled to complete Group 2. Participants were followed for approximately 48 weeks.
The patients will receive a total of 12 sessions, 3 sessions per week of sham magnetotherapy. For the simulated/sham magnetotherapy group, it will be applied in the same way as the real MT group, but the equipment will be programmed to apply 0 Gauss. The physiotherapist performing the application will not have access to the magnetotherapy parameters on the display of the device, but will only have to enter the code. After the application of sham magnetotherapy, the patient will have to perform a program of therapeutic exercise.
The patients will be screened clinically and by standard laboratory biochemical methods to determine sepsis diagnosis according to SEPSIS 3 and acute kidney injury according to KDIGO 2012 (2). Blood samples for obtaining serum/plasma of the patients will be taken on the 1st and 4th day of sepsis diagnosis.
Uptake of PrEP in the southern United States has been slow, especially in areas distant from academic medical centers that provide PrEP care. Despite underserved populations in the South having alarmingly high rates of HIV, a large percentage of at-risk individuals are not engaged in PrEP care due to limited access to academic medical centers. Mississippi (MS), the site of this proposed project, has the seventh highest incidence of HIV of any state and CBOs that provide HIV/STI testing outside of urban areas report that very few of their at-risk individuals use PrEP. Unfortunately, physicians outside of academic centers are often reluctant to prescribe PrEP because they lack the expertise, training, and the support necessary to provide comprehensive HIV prevention care. Those are at-risk do not seek PrEP from academic centers because of stigma, travel burdens, and financial concerns. To overcome these barriers, this project will develop and pilot test a program to deliver PrEP care in underserved remote communities in MS through telemedicine clinical care delivered in local CBOs. Telemedicine will allow specialists to provide care at a distance and while simultaneously enhancing the capacity of local CBOs to provide quality HIV testing and counseling, PrEP treatment, and linkage to HIV care if needed. It will allow patients to receive the highest level of medical care from trusted CBOs within their local communities. It will also enhance the CBO's mission by allowing it to provide a new, high-quality medical service.
Arm 15 will be given access to interventions 3 and 4. Video and text content will focus on educational tools about identity and determining if caregivers are affirming.
PURPOSE: A composition containing Ecklonia cava extract or fraction of the extract for preventing or treating rotaviral infection is provided to suppress cell denaturation. CONSTITUTION: A composition for preventing or treating rotaviral infection contains Ecklonia cava extract or fraction of the extract as an active ingredient. The extract is prepared using water, alcohol of C1-C4, or mixture solvent thereof. The fraction is a hexane fraction, ethyl acetate fraction, or water fraction. The rotavirus is human, porcine, bovine, or goat rotavirus. The composition is a pharmaceutical or food composition. The pharmaceutical composition is manufactured in the form of tablet, pill, powder, granule, capsule, suspension, emulsion, syrup, sterilized solution, non-aqueous solvent, emulsion, or suspension.
The invention relates to a double-layer controlled-release nanoparticle and a preparation method thereof. The nanoparticle comprises an inner core and a shell wrapping the inner core. The inner core is loaded with a first drug. According to one implementation scheme, the shell is loaded with a second drug. According to another implementation scheme, a shell material is connected with an acid-sensitivity bond which is connected with a third drug. The double-layer controlled-release nanoparticle is not removed before the drugs reach an acting portion, the drugs can be released while the carrier material is degraded, and the controlled-release effect is achieved. Meanwhile, the invention provides the preparation method of the double-layer controlled-release nanoparticle. The method includes the steps that the first drug and an inner core material are dissolved, and inner core matter is prepared through a solvent evaporation method; the inner core matter and the shell material are dissolved, and the double-layer controlled-release nanoparticle is prepared through an ionic gel method.
Anti-A.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A.beta. globulomer antibodies having a binding affinity to A.beta.(20-42) globulomer that is greater than the binding affinity of the antibody to A.beta.(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.
A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
Patients must be eligible for salvage surgical resection as deemed by the site Investigator. ONC201 will be administered orally, twice a week (2 consecutive days on and 5 days off per week) schedule at a dose of 625mg.
Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures.

Patients should also be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. [See PRECAUTIONS, General.]

Patients should also be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container.

Patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiac failure should be advised not to take this product. [See CONTRAINDICATIONS.]

Patients should be advised that Timolol Maleate Ophthalmic Solution contains benzalkonium chloride which may be absorbed by soft contact lenses. Contact lenses should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following Timolol Maleate Ophthalmic Solution administration.
A non-transitory memory component including software that, upon execution by a processor, perform operations to classify an activity performed by a user. First, the software receives activity data pertaining to an activity being performed by a user. The activity data may include one or more parameters associated with the activity including steps and time. Thereafter, a step rate is calculated based on the activity data, an activity is determined based on the calculated step rate, and an effort is determined in terms of cardiovascular intensity based, at least in part, on the calculated step rate. An appropriate effort threshold of determined cardiovascular intensity is identified based on oxygen uptake threshold. After, an activity type is classified using the effort and the activity.